• Ingmar Blumcke, Silvia Budday, Annapurna Poduri, Dennis Lal, Katja Kobow, and Stephanie Baulac.
• Institute of Neuropathology, University Hospitals Erlangen, Erlangen, Germany. Electronic address: bluemcke@uk-erlangen.de.
• Lancet Neurol. 2021 Nov 1; 20 (11): 943-955.

AbstractDuring the past decade, there have been considerable advances in understanding of the genetic and morphogenic processes underlying cortical malformations and developmental brain tumours. Focal malformations are caused by somatic (postzygotic) variants in genes related to cell growth (ie, in the mTOR pathway in focal cortical dysplasia type 2), which are acquired in neuronal progenitors during neurodevelopment. In comparison, developmental brain tumours result from somatic variants in genes related to cell proliferation (eg, in the MAP-kinase pathway in ganglioglioma), which affect proliferating glioneuronal precursors. The timing of the genetic event and the specific gene involved during neurodevelopment will drive the nature and size of the lesion, whether it is a developmental malformation or a brain tumour. There is also emerging evidence that epigenetic processes underlie a molecular memory in epileptogenesis. This knowledge will together facilitate understanding of why and how patients with these lesions have epilepsy, and could form a basis for a move towards precision medicine for this challenging cohort of patients.Copyright © 2021 Elsevier Ltd. All rights reserved.

17 keywords...

hide…